Treatment benefits patients with thalassaemia and HCV

A new study indicates that treatment with a combination of sofosbuvir and ledipasvir as a once a day single pill leads to a sustained virological response in 98% of patients with thalassaemia and HCV. “The findings are significant because, unlike other antiviral drugs, this simple treatment is expected not to be limited by drug-to-drug interactions … Continue reading “Treatment benefits patients with thalassaemia and HCV”

A new study indicates that treatment with a combination of sofosbuvir and ledipasvir as a once a day single pill leads to a sustained virological response in 98% of patients with thalassaemia and HCV.

“The findings are significant because, unlike other antiviral drugs, this simple treatment is expected not to be limited by drug-to-drug interactions with other medications usually taken by thalassaemia patients,” said Dr. Alessandra Mangia, lead author of the Alimentary Pharmacology Therapeutics study.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply